



#### **JEDI Program/JDI01**

#### **Compound Screening for SARS-CoV-2 Proteins Using MST/Dianthus**

**SARS-CoV-2 Nucleocapsid protein** 

nanoDSF / MST/ TRIC measurements

May 27, 2021



#### Status



#### nanoDSF:

- The nucleocapsid shows a well defined melting transition and good thermal stability (Tm of 45.4°C).
- However, a second very broad melting transition is observed around 65°C, indicating sample heterogeneity.
- The nucleocapsid is not significantly affected by detergents or reducing agents except DTT.
- VHH E4-3 (nanobody for the NTD) shows good thermal stability and a single melting transition.
- However, VHH H3-3 (nanobody against CTD) shows two melting events, suggesting sample heterogeneity.
- Moreover, both nanobodies were sensitive towards buffer exchange: about 50% of protein was lost during buffer exchange.



#### **Status**



#### TRIC (Dianthus):

- Nucleocapsid was successfully labelled on the His-tag with RED-Tris-NTA dyes.
- In a first experiment, nucleocapsid bound VHH E4-3 (nanobody against NTD) with a determind K<sub>D</sub> of 5.6 nM.
- However, this result was not reproducible in terms of affinity and signal-to-noise ratio and showed variation between nanobodies stored at 4°C and -80°C.
- No binding of VHH H3-3 (nanobody against CTD) to nucleocapsid was observed.

#### Labelled MST :

- For comparison, the interactions were also measured on the NT.115 instrument and yielded similar results. The same issues with the nanobodies and low reproducibility were observed.
- ➤ Overall, the QC of the nanobodies needs to be reviewed and labelled MST requires further assay optimization.



### nanoDSF

SARS-CoV-2 Nucleocapsid protein (ECJ1, PD14785-1)

### nanoDSF Assay Conditions




Protein	0.05/ 0.1/ 0.2 mg/ml SARS-CoV-2 Nucleocapsid protein (ECJ1, PD14785-1)						
Assay Buffer	50 mM TRIS pH 7.5, 150 mM NaCl						
Instrument	Prometheus NT.48						
Capillary type	nanoDSF Standard Capillaries						
Measurement parameters	LED Power: 25 % Temperature ramp: 2°C/min						



### SARS-CoV-2 Nucleocapsid protein thermal stability





Temperature [°C]

Condition	Ø T <sub>m</sub> [°C] <sup>1</sup>	Analysis mode
0.2 mg/ml	45.3	ratio
0.1 mg/ml	45.5	ratio
0.05 mg/ml	45.4	ratio

<sup>&</sup>lt;sup>1</sup> determined in singlicate

- The nucleocapsid shows a well defined melting transition with Tm of 45.4°C. A second very broad melting transition is observed around 65°C (→), suggesting sample heterogeneity.
- A concentration of 0.05 mg/ml was selected for further measurements.



### nanoDSF Assay Conditions




Protein	0.05 mg/ml SARS-CoV-2 Nucleocapsid protein (ECJ1, PD14785-1)						
Assay Buffer	8 Buffers (see table)						
Instrument	Prometheus NT.48						
Capillary type	nanoDSF Standard Capillaries						
Measurement parameters	LED Power: 70 % Temperature ramp: 2°C/min						

	Conditions
Buffer 1	20 mM TRIS pH 7.5, 150 mM NaCl
Buffer 2	20 mM TRIS pH 7.5, 150 mM NaCl, <b>0.005 % Tween20</b>
Buffer 3	20 mM TRIS pH 7.5, 150 mM NaCl, <b>0.05 % Tween20</b>
Buffer 4	20 mM TRIS pH 7.5, 150 mM NaCl, <b>0.05 % Pluronic</b>
Buffer 5	20 mM TRIS pH 7.5, 150 mM NaCl, <b>0.1 % Pluronic</b>
Buffer 6	20 mM TRIS pH 7.5, 150 mM NaCl, <b>1 mM TCEP</b>
Buffer 7	20 mM TRIS pH 7.5, 150 mM NaCl, <b>2.5 mM DTT</b>
Buffer 8	20 mM TRIS pH 7.5, 150 mM NaCl, <b>2.5 mM GSH</b>



# Effect of reducing agents and detergents on SARS-CoV-2 Nucleocapsid protein (ECJ1, PD14785-1) thermal stability





Condition	Ø T <sub>m</sub> [°C] <sup>1</sup>	s.d. [°C]	Analysis mode
Buffer 1	45.5	0.0	ratio
Buffer 2	45.2	0.1	ratio
Buffer 3	45.1	0.0	ratio
Buffer 4	45.3	0.0	ratio
Buffer 5	45.3	0.0	ratio
Buffer 6	45.4	0.0	ratio
Buffer 7	-	-	ratio
Buffer 8	45.3	0.0	ratio

<sup>&</sup>lt;sup>1</sup> determined in duplicate

 No significant impact of detergents or reducing agents on protein thermal stability was observed, except for buffer 7 (DTT), in which the protein is completely unfolded.



### nanoDSF

VHH H3-3 EEG1 (PD14991-1) CTD nanobody VHH E4-3 EEF1 (PD14989-1) NTD nanobody

### nanoDSF Assay Conditions




Protein	0.1 mg/ml VHH H3-3 EEG1 (PD14991-1) (nanobody against CTD) 0.1 mg/ml VHH E4-3 EEF1 (PD14989-1) (nanobody against NTD)				
Assay Buffer PBS					
Instrument	Prometheus NT.48				
Capillary type	nanoDSF Standard Capillaries				
Measurement parameters	LED Power: 100 % Temperature ramp: 2°C/min				



### Thermal stability of NTD and CTD nanobodys





Condition	Ø T <sub>m</sub> [°C] <sup>1</sup>	s.d. [°C]	Analysis mode
0.1 mg/ml VHH-H3-3	58.6	0.0	ratio
0.1 mg/ml VHH-E4-3	62.5	0.0	

<sup>&</sup>lt;sup>1</sup> determined in duplicate

- VHH-H3-3 (CTD nanobody) shows a main melting transition at 58.6°C and a minor melting transition at ~48°C (→), suggesting sample heterogeneity.
- VHH E4-3 (NTD nanobody) shows a well defined melting transition with Tm of 62.5°C.



0.1 mg/ml VHH H3-3

## TRIC (Dianthus)

SARS-CoV-2 Nucleocapsid protein (ECJ1, PD14785-1)


### TRIC Assay Conditions




Fluor. Molecule	25 nM RED-tris-NTA 1 <sup>st</sup> gen. 25 nM RED-tris-NTA 2 <sup>nd</sup> gen.						
Fluorophore	RED-tris-NTA 1 <sup>st</sup> and 2 <sup>nd</sup> gen.						
Instrument	Dianthus NT.23PicoDuo						
Measurement parameter	LED Power: 13 % (nano detector)  TRIC settings: 1 - 5 - 1 (s) (initial fluorescence – MST on time – back-diffusion)  Singlicates						
Assay buffer	50 mM HEPES pH 7.5, 150 mM NaCl, 0.05% Tween20						
Titrant	SARS-CoV-2 Nucleocapsid protein (ECJ1, PD14785-1) 1 μM – 0.49 nM (12 conc.)						

# RED-tris-NTA 1<sup>st</sup> and 2<sup>nd</sup> gen. vs. SARS-CoV-2 Nucleocapsid protein (ECJ1, PD14785-1)





RED-tris-NTA 1st gen.



RED-tris-NTA 2<sup>nd</sup> gen.

Fluorophore	Fluor. Molecule	Titrant	K <sub>D</sub> [M]	Lower confidence [M]	Upper confidence [M]	ΔFnorm [‰]	Signal / Noise	TRIC On [s]	Comment
RED-tris-NTA 1st gen.	RED-tris-NTA 1st gen.	Nucleocapsid	4.9E-09	2.3E-09	1.0E-08	44.7	19.6	5	aggregation
RED-tris-NTA 2 <sup>nd</sup> gen.	RED-tris-NTA 2 <sup>nd</sup> gen.	Nucleocapsid	6.7E-09	2.3E-09	2.0E-08	45.7	10.6	5	

- RED-tris-NTA 1<sup>st</sup> gen. binds with a determined  $K_D$  of 4.9 nM the protein, some aggregation was observed.
- RED-tris-NTA  $2^{nd}$  gen. binds with a determined  $K_D$  of 6.7 nM the protein.
- Both dyes can be used to non-covalently label the nucleocapsid.



### TRIC Assay Conditions




Fluor. Molecule	50 nM SARS-CoV-2 Nucleocapsid protein (ECJ1, PD14785-1)							
Fluorophore	RED-tris-NTA 2 <sup>nd</sup> gen.							
	100 nM protein / 25 nM dye							
Labelling conditions	Incubation time: 30 min							
	Centrifugation: 10 min at 15000	g						
Instrument	Dianthus NT.23PicoDuo							
	LED Power: 26 % (nano detector)							
Measurement parameter	TRIC settings: 1 - 5 - 1 (s) (initial fluorescence – MST on time – back-diffusion)							
	Duplicates							
	Buffer 1: 20 mM HEPES pH 7.5, 150 mM NaCl, 0.05% Tween20 (56% Protein lose at buffer exchange of VHH E4-3)							
	·		05% Tween20 (54% Protein lose at buffer exchange of VHH E4-3)					
Assay buffer	· ·							
	Buffer 3: 20 mM HEPES pH 7.5, 150 mM NaCl, 0.1% Pluronic (59% Protein lose at buffer exchange of VHH E4-3)							
	Builet 4. 20 million rier 23 pri 7.3,	Buffer 4: 20 mM HEPES pH 7.5, 150 mM NaCl, 0.1% PEG 8000, 0.1% Pluronic (54% Protein lose at buffer exchange of VHH E4-3)						
	VHH E4-3 (nanobody against							
Titrant	NTD)	EEF1 (PD14989-1)	2 μM – 0.98 nM (12 conc.)					




# RED-tris-NTA 2<sup>nd</sup> gen. labelled SARS-CoV-2 Nucleocapsid protein (ECJ1, PD14785-1) vs. VHH E4-3 (NTD nanobody)





Buffer 1



Buffer 2


Fluorophore	Fluor. Molecule	Titrant	K <sub>D</sub> [M]	Lower confidence [M]	Upper confidence [M]	ΔFnorm [‰]	Signal / Noise	TRIC On [s]	Comment
RED-tris-NTA 2 <sup>nd</sup> gen.	Nucleocapsid	VHH E4-3	-	-	-	-	-	5	Buffer 1, Aggregation
RED-tris-NTA 2 <sup>nd</sup> gen.	Nucleocapsid	VHH E4-3	5.6E-09	1.0E-9	3.0E-08	- 5.1	8.2	5	Buffer 2

- RED-tris-NTA 2<sup>nd</sup> gen. labelled Nucleocapsid does not bind VHH E4-3 in buffer 1, aggregation was observed.
- RED-tris-NTA 2<sup>nd</sup> gen. labelled Nucleocapsid binds VHH E4-3 with a determined K<sub>D</sub> of 5.6 nM in buffer 2.




# RED-tris-NTA 2<sup>nd</sup> gen. labelled SARS-CoV-2 Nucleocapsid protein (ECJ1, PD14785-1) vs. VHH E4-3 (NTD nanobody)





Buffer 3



Buffer 4

Fluorophore	Fluor. Molecule	Titrant	K <sub>D</sub> [M]	Lower confidence [M]	Upper confidence [M]	ΔFnorm [‰]	Signal / Noise	TRIC On [s]	Comment
RED-tris-NTA 2 <sup>nd</sup> gen.	Nucleocapsid	VHH E4-3	-	-	-	-	-	5	Buffer 3, Aggregation
RED-tris-NTA 2 <sup>nd</sup> gen.	Nucleocapsid	VHH E4-3	-	-	-	-	-	5	Buffer 4, Aggregation

- RED-tris-NTA 2<sup>nd</sup> gen. labelled Nucleocapsid does not bind VHH E4-3 in buffer 3, aggregation was observed.
- RED-tris-NTA 2<sup>nd</sup> gen. labelled Nucleocapsid does not bind VHH E4-3 in buffer 4, aggregation was observed.



### TRIC Assay Conditions




Fluor.	50 nM SARS-CoV-2 Nucleocapsid protein (ECJ1, PD14785-1)								
Molecule	35 IIII 37 III COT 2 Maciocapsia protein (263 1, 1 2 1 17 03 1)								
Fluorophore	RED-tris-NTA 2 <sup>nd</sup> gen.								
Labelling	100 nM protein / 25 nM dye								
	Incubation time: 30 min								
conditions	Centrifugation: 10 min at 15000g								
Instrument	Dianthus NT.23PicoDuo								
Measurement	LED Power: 26 % (nano detector)								
	TRIC settings: 1 - 5 - 1 (s) (initial fluorescence – MST on time – back-diffusion)								
parameter	Duplicates								
Assay buffer	Buffer 2: 20 mM HEPES pH 7.5, 150 mM NaCl, 0.1% PEG 8000, 0.05% Tween20								
Titrant	VHH E4-3 (nanobody against NTD)								
	VHH H3-3 (nanobody against CTD) EEG1 (PD14991-1)								

Titrant	Buffer	Protein loss during buffer exchange
VHH E4-3	Buffer1	41%
VHH H3-3	Buffer1	45%




### RED-tris-NTA 2<sup>nd</sup> gen. labelled SARS-CoV-2 Nucleocapsid protein (ECJ1, PD14785-1) vs. VHH E4-3 and VHH H3-3





**VHH E4-3** (nanobody against NTD)



**VHH H3-3** (nanobody against CTD)


Fluorophore	Fluor. Molecule	Titrant	K <sub>D</sub> [M]	Lower confidence [M]	Upper confidence [M]	ΔFnorm [‰]	Signal / Noise	TRIC On [s]	Comment
RED-tris-NTA 2 <sup>nd</sup> gen.	Nucleocapsid	VHH E4-3 (stored at 4°C)	-	-	-	-	-	5	Aggregation
RED-tris-NTA 2 <sup>nd</sup> gen.	Nucleocapsid	VHH H3-3 (stored at 4°C)	-	-	<del>-</del>	-	=	5	Aggregation

- RED-tris-NTA 2<sup>nd</sup> gen. labelled Nucleocapsid shows strong aggregation and no clear binding to VHH E4-3 (stored at 4°C) using the previously optimized assay buffer.
- RED-tris-NTA 2<sup>nd</sup> gen. labelled Nucleocapsid does not bind VHH H3-3, aggregation was observed.



## RED-tris-NTA 2<sup>nd</sup> gen. labelled SARS-CoV-2 Nucleocapsid protein (ECJ1, PD14785-1) vs. VHH E4-3 and VHH H3-3





Fluorophore	Fluor. Molecule	Titrant	K <sub>D</sub> [M]	confidence [M]	confidence [M]	ΔFnorm [‰]	Signal / Noise	On [s]	Comment
RED-tris-NTA 2 <sup>nd</sup> gen.	Nucleocapsid	VHH E4-3 (stored at -80°C)	~6.6E-08	-	=	-	-	5	Aggregation, potential binding
RED-tris-NTA 2 <sup>nd</sup> gen.	Nucleocapsid	VHH H3-3 (stored at -80°C)	-	-	-	-	-	5	Aggregation

- RED-tris-NTA 2<sup>nd</sup> gen. labelled Nucleocapsid shows aggregation and only potential binding to VHH E4-3 (stored at -80°C) with reduced affinity compared to the previous measurement.
- RED-tris-NTA 2<sup>nd</sup> gen. labelled Nucleocapsid does not bind VHH H3-3, aggregation was observed.



### TRIC Summary:



#### Binding affinity of 2 nanobodies to SARS-CoV-2 Nucleocapsid protein (ECJ1, PD14785-1)

Titrant	K <sub>D</sub> [M]	Lower confidence [M]	Upper confidence [M]	ΔFnorm [‰]	Signal / Noise	TRIC On [s]	Comment
VHH E4-3	-	-	-	-	-	5	Buffer 1, Aggregation
VHH E4-3	5.6E-09	1.0E-9	3.0E-08	- 5.1	8.2	5	Buffer 2
VHH E4-3	-	-	-	-	-	5	Buffer 3, Aggregation
VHH E4-3	-	-	-	-	-	5	Buffer 4, Aggregation
VHH E4-3	-	-	-	-	-	5	Buffer 2, aggregation (4°C stored nanobody, after 2 days)
VHH H3-3	-	-	-	-	+	5	Buffer 2, aggregation (4°C stored nanobody, after 2 days)
VHH E4-3 (stored at -	~6.6E-08	_	_	_	-	5	Buffer 2, Aggregation (-80°C stored
80°C)	0.02 00					J	nanobody, after 2 days)
VHH H3-3 (stored at	_	-	-	_	_	5	Buffer 2, Aggregation (-80°C stored
-80°C)						J	nanobody, after 2 days)



### Labelled MST

SARS-CoV-2 Nucleocapsid protein (ECJ1, PD14785-1)

### MST labelled assay conditions





Fluor. Molecule	50 nM SARS-CoV-2 Nucleocapsid protein (ECJ1, PD14785-1)								
Fluorophore	RED-tris-NTA 2 <sup>nd</sup> gen.								
	100 nM protein / 25 nM dye								
<b>Labelling conditions</b>	Incubation time: 30 min								
	Centrifugation: 10 min at 15000g								
Instrument	Monolith NT.115 (03)								
Capillary type	Monolith™ NT.115 Series MST Premium Coated Capillaries								
	LED Power: 100 %								
M	MST Power: 40 %								
Measurement parameter	MST settings: 3 – 20 – 1 (s) (initial fluorescence – MST on time – back-diffusion)								
	Duplicate								
	Buffer 1: 20 mM HEPES pH 7.5, 150 mM NaCl, 0.05% Tween20 (56% Protein lose at buffer exchange of VHH E4-3)								
Access builton	Buffer 2: 20 mM HEPES pH 7.5, 150 mM NaCl, 0.1% PEG 8000, 0.05% Tween20 (54% Protein lose at buffer exchange of VHH E4-3)								
Assay buffer	Buffer 3: 20 mM HEPES pH 7.5, 150 mM NaCl, 0.1% Pluronic (59% Protein lose at buffer exchange of VHH E4-3)								
	Buffer 4: 20 mM HEPES pH 7.5, 150 mM NaCl, 0.1% PEG 8000, 0.1% Pluronic (54% Protein lose at buffer exchange of VHH E4-3)								
Titrant	VHH E4-3 (NTD nanobody) EEF1 (PD14989-1) (stored at 4°C) 2 $\mu$ M – 0.98 nM (12 conc.)								



# RED-tris-NTA 2<sup>nd</sup> gen. labelled SARS-CoV-2 Nucleocapsid protein (ECJ1, PD14785-1) vs. VHH E4-3 (NTD nanobody)









Fluorophore	Fluor. Molecule	Titrant	K <sub>D</sub> [M]	K <sub>D</sub> Confidence [M]	ΔFnorm [‰]	Signal / Noise	MST on [s]	Comment
RED-tris-NTA 2 <sup>nd</sup> gen.	Nucleocapsid	VHH E4-3	<1.0E-09	2.7E-18 - 0.04	14.3	6.1	20	Buffer 1
RED-tris-NTA 2 <sup>nd</sup> gen.	Nucleocapsid	VHH E4-3	1.1E-09	4.0E-12 – 3.4E-7	19.2	8.3	20	Buffer 2

- RED-tris-NTA  $2^{nd}$  gen. labelled Nucleocapsid binds with a determined  $K_D < 1$  nM VHH-E4-3 in buffer 1. Due to the high protein concentration, the affinity cannot be accurately determined.
- RED-tris-NTA 2<sup>nd</sup> gen. labelled Nucleocapsid binds with a determined K<sub>D</sub> of 1.1 nM VHH-E4-3 in buffer 2.

# RED-tris-NTA 2<sup>nd</sup> gen. labelled SARS-CoV-2 Nucleocapsid protein (ECJ1, PD14785-1) vs. VHH E4-3 (NTD nanobody)







Fluorophore	Fluor. Molecule	Titrant	K <sub>D</sub> [M]	K <sub>D</sub> Confidence [M]	ΔFnorm [‰]	Signal / Noise	MST on [s]	Comment
RED-tris-NTA 2 <sup>nd</sup> gen.	Nucleocapsid	VHH E4-3	2.4E-09	3.0E-12 – 1.8E-06	10.6	4.6	20	Buffer 3
RED-tris-NTA 2 <sup>nd</sup> gen.	Nucleocapsid	VHH E4-3	2.8E-09	4.0E-12 – 2.3E-06	13.7	4.0	20	Buffer 4

- RED-tris-NTA 2<sup>nd</sup> gen. labelled Nucleocapsid binds with a determined K<sub>D</sub> of 2.4 nM VHH-E4-3 in buffer 3.
- RED-tris-NTA 2<sup>nd</sup> gen. labelled Nucleocapsid binds with a determined K<sub>D</sub> of 2.8 nM VHH-E4-3 in buffer 4.
- Signal-to-noise ratio is low in both buffers.



### MST labelled assay conditions




Fluor. Molecule	50 nM SARS-CoV-2 Nucleocapsid protein (ECJ1, PD14785-1)								
Fluorophore	RED-tris-NTA 2 <sup>nd</sup> gen.								
	100 nM protein / 25 nM dye								
<b>Labelling conditions</b>	Incubation time: 30 min								
	Centrifugation: 10 min at 15000g								
Instrument	Monolith NT.115 (03)								
Capillary type	Monolith <sup>™</sup> NT.115 Series MST Premium Coated Capillaries								
	LED Power: 80 %								
Na	MST Power: 40 % and 60 %								
Measurement parameter	MST settings: 3 – 20 – 1 (s) (initial fluorescence – MST on time – back-diffusion)								
	Duplicate								
Assay buffer	Buffer 2: 20 mM HEPES pH 7.5, 150 mM NaCl, 0.1% PEG 8000, 0.05% Tween20								
Tituent	VHH E4-3 (nanobody against NTD) EEF1 (PD14989-1)								
Titrant	VHH H3-3 (nanobody against CTD) EEG1 (PD14991-1) 1 μM – 0.49 nM (12 conc.)								



# RED-tris-NTA 2<sup>nd</sup> gen. labelled SARS-CoV-2 Nucleocapsid protein (ECJ1, PD14785-1) vs. VHH E4-3 (NTD nanobody)







Fluorophore	Fluor. Molecule	Titrant	K <sub>D</sub> [M]	K <sub>D</sub> Confidence [M]	ΔFnorm [‰]	Signal / Noise	MST on [s]	Comment
RED-tris-NTA 2 <sup>nd</sup> gen.	Nucleocapsid	VHH E4-3 (stored at 4°C)	-	-	-	-	20	Medium MST, low S/N


• RED-tris-NTA 2<sup>nd</sup> gen. labelled Nucleocapsid does not bind VHH-E4-3 stored at 4°C in the previously optimized assay buffer.




# RED-tris-NTA 2<sup>nd</sup> gen. labelled SARS-CoV-2 Nucleocapsid protein (ECJ1, PD14785-1) vs. VHH E4-3 (NTD nanobody)



Medium MST High MST






Fluorophore	Fluor. Molecule	Titrant	K <sub>D</sub> [M]	K <sub>D</sub> Confidence [M]	ΔFnorm [‰]	Signal / Noise	MST on [s]	Comment
RED-tris-NTA 2 <sup>nd</sup> gen.	Nucleocapsid	VHH E4-3 (stored at -80°C)	7.5E-10	2.6E-14 – 2.1E-05	11.8	4.5	20	Medium MST, low S/N
RED-tris-NTA 2 <sup>nd</sup> gen.	Nucleocapsid	VHH E4-3 (stored at -80°C)	2.4E-08	-	77.1	16.7	20	High MST

- RED-tris-NTA  $2^{nd}$  gen. labelled Nucleocapsid binds VHH-E4-3 stored at -80°C with a determined  $K_D$  of 0.75 nM, but the signal-to-noise ratio is low (MST medium).
- At high MST power, RED-tris-NTA 2<sup>nd</sup> gen. labelled Nucleocapsid binds VHH-E4-3 with a determined K<sub>D</sub> of 23.5 28 nM. CONFIDENTIAL

# RED-tris-NTA 2<sup>nd</sup> gen. labelled SARS-CoV-2 Nucleocapsid protein (ECJ1, PD14785-1) vs. VHH H3-3 (CTD nanobody)



#### Medium MST




Fluorophore	Fluor. Molecule	Titrant	K <sub>D</sub> [M]	K <sub>D</sub> Confidence [M]	ΔFnorm [‰]	Signal / Noise	MST on [s]	Comment
RED-tris-NTA 2 <sup>nd</sup> gen.	Nucleocapsid	VHH H3-3 (stored at 4°C)	-	-	-	-	20	Medium MST


• RED-tris-NTA 2<sup>nd</sup> gen. labelled Nucleocapsid does not bind VHH-H3-3 stored at 4°C in the previously optimized assay buffer.



# RED-tris-NTA 2<sup>nd</sup> gen. labelled SARS-CoV-2 Nucleocapsid protein (ECJ1, PD14785-1) vs. VHH H3-3 (CTD nanobody)







Fluorophore	Fluor. Molecule	Titrant	K <sub>D</sub> [M]	K <sub>D</sub> Confidence [M]	ΔFnorm [‰]	Signal / Noise	MST on [s]	Comment
RED-tris-NTA 2 <sup>nd</sup> gen.	Nucleocapsid	VHH H3-3 (stored at -80°C)	-	-	-	-	20	Medium MST
RED-tris-NTA 2 <sup>nd</sup> gen.	Nucleocapsid	VHH H3-3 (stored at -80°C)	<1.0E-09	7.0E-12 – 2.1E-8	11.8	7.3	20	High MST

- RED-tris-NTA 2<sup>nd</sup> gen. labelled Nucleocapsid does not bind VHH-H3-3 stored at -80°C (MST medium).
- At high MST power, RED-tris-NTA 2<sup>nd</sup> gen. labelled Nucleocapsid binds VHH-H3-3 with a determined  $K_D < 1$  nM. Due to the high protein concentration, the affinity cannot be accurately determined.

ONFIDENTIAL

#### MST summary:



Binding affinity of 2 nanobodys to RED-tris-NTA 2<sup>nd</sup> labelled SARS-CoV-2 Nucleocapsid protein (ECJ1, PD14785-1)

Fluorophore	Fluor. Molecule	Titrant	K <sub>D</sub> [M]	K <sub>D</sub> Confidence [M]	ΔFnorm [‰]	Signal / Noise	MST ON [s]	Comment
RED-tris-NTA 2 <sup>nd</sup> gen.	Nucleocapsid	VHH E4-3 (NTD nanobody)	7.5E-10	2.6E-14 – 2.1E-05	11.8	4.5	20	Medium MST, low S/N
RED-tris-NTA 2 <sup>nd</sup> gen.	Nucleocapsid	VHH E4-3 (NTD nanobody)	2.4E-08	-	77.1	16.7	20	High MST
RED-tris-NTA 2 <sup>nd</sup> gen.	Nucleocapsid	VHH H3-3 (CTD nanobody)	-	-	-	-	20	Medium MST
RED-tris-NTA 2 <sup>nd</sup> gen.	Nucleocapsid	VHH H3-3 (CTD nanobody)	<1.0E-09	7.0E-12 – 2.1E-8	11.8	7.3	20	High MST

#### Next steps



- Discuss nanobody QC
- Further TRIC/MST assay optimization (additional Nucleocapsid protein required)







**Crelux GmbH** a WuXi AppTec company

Dr. Saskia Villinger Senior Scientist and Deputy Head of Biophysics & Screening Am Klopferspitz 19a 82152 Martinsried Germany

Saskia.Villinger@wuxiapptec.com www.crelux.com www.wuxiapptec.com

